Category - Developments

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) completed the clinical trial component, or Stage 3, of its Hodgkin’s lymphoma (HL) test, known as Telo-HL, and has submitted the data to its statistics consulting partner...

Ortho Regenerative Technologies will begin trading today on the Canadian Securities Exchange under the stock symbol, ORTH. Ortho RTi is an emerging orthopedic and sports medicine technology company with a focus on novel...

Researchers in Australia and the U.S. say they have created a highly elastic surgical glue that can quickly seal even the toughest wounds, without staples or stitches. In a paper published this week in Science...

Theratechnologies (TSX:TH) presented positive 48-week efficacy and safety results at the IDWeek 2017 conference in San Diego for ibalizumab in patients infected with multidrug resistant HIV-1, who completed the 24-week...

Mallinckrodt (NYSE:MNK) has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and...

Titan Pharmaceuticals (NASDAQ:TTNP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are collaborating to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use...

Alcobra (NASDAQ:ADHD) announced plans to merge with closely held Arcturus Therapeutics in an all-stock transaction, creating an RNA-focused company with a 40-60 split in ownership, respectively. Arcturus’ technology...

Mateon Therapeutics (OTCQX:MATN) terminated its Phase 2/3 FOCUS after a third scheduled interim analysis of CA4P in combination with bevacizumab (Avastin) and physician’s choice chemotherapy in patients with platinum...

The FDA has approved Arkis BioSciences’ CerebroFlo external ventricular drain (EVD) catheter that includes Interface Biologics’ Endexo technology. The CerebroFlo catheter has demonstrated a 99% reduction in thrombus...

American CryoStem (OTC:CRYO) has expanded its relationship with Health Innovative Technology (HIT) of Hong Kong. After more than two years as CryoStem’s licensee in Hong Kong, HIT has licensed the patent rights to...